{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:08:17Z","timestamp":1784354897320,"version":"3.55.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.soc.2004.11.001","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T13:29:14Z","timestamp":1113830954000},"page":"321-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bladder Cancer\u2014Resection\/Ablation"],"prefix":"10.1016","volume":"14","author":[{"given":"Federico A.","family":"Corica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2004.11.001_bib1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.soc.2004.11.001_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0302-2838(02)00466-9","article-title":"Superficial bladder tumors","volume":"42","author":"Chopin","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2003.09.013","article-title":"Bladder carcinoma in situ in 2003: state of the art","volume":"45","author":"Witjes","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","article-title":"Primary superficial bladder cancer risk groups according to progression, mortality and recurrence","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-5347(01)61899-8","article-title":"Comparison of screening methods in the detection of bladder cancer","volume":"161","author":"Ramakumar","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","article-title":"Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses","volume":"61","author":"Lotan","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1464-410X.2003.04528.x","article-title":"Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer","volume":"92","author":"Friedrich","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.soc.2004.11.001_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0302-2838(02)00448-7","article-title":"Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology","volume":"42","author":"Placer","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib9","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0022-5347(05)64270-X","article-title":"Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer","volume":"168","author":"Sarosdy","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/01.ju.0000134347.14643.ab","article-title":"A side by side comparison of cytology and biomarkers for bladder cancer detection","volume":"172","author":"Schroeder","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/01.ju.0000107826.78479.90","article-title":"Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer","volume":"171","author":"Shariat","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib12","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials","volume":"164","author":"van der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(02)01920-9","article-title":"Impact of a second transurethral resection on the staging of T1 bladder cancer","volume":"60","author":"Dalbagni","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0302-2838(03)00157-X","article-title":"Significance of random bladder biopsies in superficial bladder cancer","volume":"44","author":"May","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000474774","article-title":"Value of random mucosal biopsies in the management of superficial bladder cancer","volume":"22","author":"Mufti","year":"1992","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/0959-8049(94)E0133-O","article-title":"Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer","volume":"30","author":"Kiemeney","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soc.2004.11.001_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1442-2042.2003.00724.x","article-title":"Multiple biopsies of normal-looking urothelium in patients with superficial bladder cancer: are they necessary?","volume":"10","author":"Fujimoto","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/00365598609024496","article-title":"A prospective randomized study on neodymium-YAG laser irradiation versus TUR in the treatment of urinary bladder cancer","volume":"20","author":"Beisland","year":"1986","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.soc.2004.11.001_bib21","first-page":"173","article-title":"A randomized trial of observation versus photodynamic therapy after TUR for superficial papillary bladder cancer","volume":"10","author":"Dugan","year":"1991","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.soc.2004.11.001_bib22","first-page":"3","article-title":"Intravesical therapy option for bladder malignancy","volume":"May","author":"Bird","year":"2003","journal-title":"Contemp Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib23","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)68208-0","article-title":"Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association","volume":"162","author":"Smith","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib24","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.soc.2004.11.001_bib25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib27","first-page":"4270","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"Journal of Chemical Oncology"},{"key":"10.1016\/j.soc.2004.11.001_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.soc.2004.11.001_bib29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","article-title":"Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup","volume":"161","author":"Solsona","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib30","first-page":"65","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.soc.2004.11.001_bib34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0090-4295(01)01324-3","article-title":"Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years","volume":"58","author":"Patard","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","article-title":"Tumor progression and survival in patients with T1G3 bladder tumors: 15-year outcome","volume":"80","author":"Herr","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.soc.2004.11.001_bib41","first-page":"1964","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"68","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"Suppl","key":"10.1016\/j.soc.2004.11.001_bib42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1569-9056(03)80754-6","article-title":"Comparison of standard BCG dose (81mg) versus three-fold reduced dose (27mg) in high-risk superficial bladder cancer (T1G3, Tis). A Cueto prospective randomized study #95012","volume":"2","author":"Martinez-Pineiro","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib43","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1464-410X.2003.04764.x","article-title":"Bacillus Calmette-Guerin therapy in stage Ta\/T1 bladder cancer: prognostic factors for time to recurrence and progression","volume":"93","author":"Andius","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.soc.2004.11.001_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2004.04.011","article-title":"European Association of Urology. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma","volume":"46","author":"Oosterlink","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib46","first-page":"81","article-title":"Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig","volume":"378","author":"De Boer","year":"1992","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.soc.2004.11.001_bib47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib48","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"issue":"Suppl","key":"10.1016\/j.soc.2004.11.001_bib49","first-page":"14","article-title":"Intravesical therapy for refractory transitional cell cancer in situ","volume":"May","author":"Greenberg","year":"2003","journal-title":"Contemp Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00042307-200409000-00005","article-title":"Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures","volume":"14","author":"Joudi","year":"2004","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib51","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0090-4295(96)00375-5","article-title":"Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer","volume":"48","author":"Stricker","year":"1996","journal-title":"Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib53","first-page":"257","article-title":"BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder","volume":"67","author":"Bercovich","year":"1995","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.soc.2004.11.001_bib54","unstructured":"Keane TE, Eldaieef SM, Clarke HS, Daily PP. Combination intravesical immunotherapy (BCG plus interferon alpha -2B) in high-grade recurrent superficial transitional cell carcinoma [abstract 48]. SEAUA 2003;Mar."},{"key":"10.1016\/j.soc.2004.11.001_bib55","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O'Donnell","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib56","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib58","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0022-5347(05)65157-9","article-title":"Contemporary management of stage T1 transitional cell carcinoma of the bladder","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/B:UROL.0000032688.37789.7c","article-title":"T1G3 bladder cancer\u2014indications for early cystectomy","volume":"36","author":"Masood","year":"2004","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.soc.2004.11.001_bib60","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high-risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib61","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib62","first-page":"105","article-title":"European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer","volume":"41","author":"Oosterlink","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib63","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0090-4295(01)01496-0","article-title":"Routine bladder biopsy after BCG treatment: is it necessary?","volume":"59","author":"Skemp","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1464-410X.1995.tb07310.x","article-title":"Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies?","volume":"75","author":"Morris","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000020010","article-title":"Late recurrence and progression after a long tumor-free period in primary Ta and T1 bladder cancer","volume":"36","author":"Fujii","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib66","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0090-4295(98)00480-4","article-title":"Conservative therapy for stage T1b grade 3 transitional cell carcinoma of the bladder","volume":"53","author":"Gohji","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib67","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with BCG for transitional cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.soc.2004.11.001_bib68","first-page":"3","article-title":"Superficial bladder cancer-insight and expertise","volume":"May","author":"Schellhammer","year":"2004","journal-title":"Contemp Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00005392-200101000-00012","article-title":"De novo muscle invasive bladder cancer: is there a change in trend?","volume":"165","author":"Vaidya","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib70","doi-asserted-by":"crossref","unstructured":"Grossman HB. Contemp Urol 2004;(Suppl):10.","DOI":"10.1145\/1036474.1036476"},{"key":"10.1016\/j.soc.2004.11.001_bib71","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0022-5347(05)64854-9","article-title":"Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population","volume":"168","author":"Henningsohn","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1464-410x.2000.00454.x","article-title":"The changing pattern of mortality and morbidity from radical cystectomy","volume":"85","author":"Rosario","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.soc.2004.11.001_bib73","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.urology.2003.12.035","article-title":"Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor","volume":"63","author":"Lee","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib74","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0022-5347(05)67522-2","article-title":"Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy","volume":"63","author":"Paik","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1148\/radiology.193.1.8090898","article-title":"Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging","volume":"193","author":"Kim","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.soc.2004.11.001_bib76","first-page":"133","article-title":"Utility of computerized tomography in determining the extent of infiltrating bladder tumors: our experience","volume":"56","author":"Jalon-Monzon","year":"2003","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib77","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/01.ju.0000135530.59860.7d","article-title":"Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection","volume":"172","author":"Holzbeierlein","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib78","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/1097-0142(195605\/06)9:3<551::AID-CNCR2820090319>3.0.CO;2-2","article-title":"The prognosis with untreated bladder tumors","volume":"9","author":"Prout","year":"1956","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2004.11.001_bib79","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0022-5347(01)64818-3","article-title":"Long-term follow-up of a bladder carcinoma cohort: questionable value of radical radiotherapy","volume":"157","author":"Holmang","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib80","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0022-5347(05)67267-9","article-title":"The current status of bladder preservation in the treatment of muscle invasive bladder cancer","volume":"164","author":"Kim","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00345-002-0255-6","article-title":"Contemporary cystectomy and urinary diversion","volume":"20","author":"Madersbacher","year":"2002","journal-title":"World J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib82","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-5347(01)66429-2","article-title":"Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup","volume":"155","author":"Schoenberg","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib83","unstructured":"Lee K, et al. During cystectomy men and women are not equal. Urology Times 2004; February 15."},{"key":"10.1016\/j.soc.2004.11.001_bib84","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0022-5347(01)61953-0","article-title":"Anatomical anterior exenteration with urethral and vaginal preservation: illustrated surgical method","volume":"161","author":"Schoenberg","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib85","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-5347(05)64849-5","article-title":"Pathological findings of gynecologic organs obtained at female radical cystectomy","volume":"168","author":"Chang","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib86","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0090-4295(98)00099-5","article-title":"Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women","volume":"51","author":"Stein","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib87","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0022-5347(01)66223-2","article-title":"Ureteral frozen section analysis during cystectomy: a reassessment","volume":"155","author":"Schoenberg","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib88","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0022-5347(01)64312-X","article-title":"Ureteral carcinoma in situ at radical cystectomy: does the margin matter?","volume":"158","author":"Silver","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib89","first-page":"666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.soc.2004.11.001_bib90","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/01.ju.0000052721.61645.a3","article-title":"Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base","volume":"169","author":"Konety","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib91","first-page":"44","article-title":"Current strategies for managing locally advanced bladder cancer","volume":"16","author":"Queck","year":"2004","journal-title":"Contemp Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib92","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0090-4295(02)02116-7","article-title":"Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy","volume":"61","author":"Herr","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.soc.2004.11.001_bib93","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1464-410x.2000.00614.x","article-title":"Lymphadenectomy in patients with transitional cell cancer of the urinary bladder","volume":"85","author":"Leissner","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.soc.2004.11.001_bib94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.ju.0000072422.69286.0e","article-title":"Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density","volume":"170","author":"Stein","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib95","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0022-5347(01)62229-8","article-title":"Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall","volume":"160","author":"Poulsen","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib96","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urolonc.2004.04.030","article-title":"The evolving role of pelvic lymphadenectomy in the treatment of bladder cancer","volume":"22","author":"Sanderson","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.soc.2004.11.001_bib97","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.ju.0000102302.26806.fb","article-title":"Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study","volume":"171","author":"Leissner","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib98","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(17)44050-X","article-title":"Incidence, extent and location of unsuspected pelvic lymph node metastasis in patients undergoing radical cystectomy for bladder cancer","volume":"137","author":"Wishnow","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib99","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-200101000-00015","article-title":"Outcomes of patients with grossly node positive bladder cancer after pelvic node dissection and cystectomy","volume":"165","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib100","first-page":"23","article-title":"Improving outcome after bladder cancer surgery","volume":"15","author":"Herr","year":"2003","journal-title":"Contemp Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib101","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/01.ju.0000121604.58067.95","article-title":"Stage specific lymph node metastasis mapping in radical cystectomy specimens","volume":"171","author":"Vazina","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib102","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-5347(05)66067-3","article-title":"Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy","volume":"166","author":"Mills","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1464-410X.2004.04557.x","article-title":"Does extended lymphadenectomy increase the morbidity of radical cystectomy?","volume":"93","author":"Brossner","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.soc.2004.11.001_bib104","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loeher","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2004.11.001_bib105","first-page":"1050","article-title":"A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.soc.2004.11.001_bib106","first-page":"3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.soc.2004.11.001_bib107","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soc.2004.11.001_bib108","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","author":"Stadler","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2004.11.001_bib109","first-page":"4005","article-title":"Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC","volume":"19","author":"Millikan","year":"2001","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.soc.2004.11.001_bib110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0022-5347(17)38368-4","article-title":"The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial","volume":"145","author":"Skinner","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib111","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0022-5347(17)47789-5","article-title":"Editorial comment re: Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following csytectomy for invasive bladder cancer: a prospective comparative trial","volume":"145","author":"Raghavan","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005392-199501000-00019","article-title":"Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience","volume":"153","author":"Stockle","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib113","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-5347(01)66430-9","article-title":"A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer","volume":"155","author":"Freiha","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib114","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.2000.18.18.3247","article-title":"Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group","volume":"18","author":"Bellmunt","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2004.11.001_bib115","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2001.19.12.3018","article-title":"Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"19","author":"Meluch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2004.11.001_bib116","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/cncr.11726","article-title":"A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma","volume":"98","author":"Gitlitz","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2004.11.001_bib117","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clon.2003.10.001","article-title":"A meta-analysis of randomized trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice?","volume":"16","author":"Shelley","year":"2004","journal-title":"Clin Oncol"},{"key":"10.1016\/j.soc.2004.11.001_bib118","first-page":"690","article-title":"Radical cystectomy for bladder cancer today\u2014a homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.soc.2004.11.001_bib119","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-5347(17)38244-7","article-title":"Results of contemporary radical cystectomy for invasive bladder: a clinicopathological study with an emphasis on the inadequacy of the TNM classification","volume":"145","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib120","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0022-5347(17)39675-1","article-title":"Local recurrence and survival following nerve-sparing cystoprostatectomy","volume":"144","author":"Brendler","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib121","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib122","first-page":"275","article-title":"Grading and staging of bladder carcinoma in transurethral resection specimens-correlation with 105 matched cystectomy specimens","volume":"113","author":"Cheng","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.soc.2004.11.001_bib123","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0360-3016(94)90003-5","article-title":"Organ-sparing treatment in advanced bladder cancer: a 10-year experience","volume":"30","author":"Dunst","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2004.11.001_bib124","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM199311043291903","article-title":"Selective bladder preservation by combination treatment of invasive bladder cancer","volume":"329","author":"Kaufman","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soc.2004.11.001_bib125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0360-3016(97)00579-8","article-title":"Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer","volume":"40","author":"Sauer","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2004.11.001_bib126","first-page":"3061","article-title":"Combined modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"Rodel","year":"2002","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.soc.2004.11.001_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6601852","article-title":"Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer","volume":"90","author":"Hussain","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.soc.2004.11.001_bib128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2004.11.001_bib129","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0302-2838(02)00581-X","article-title":"A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire","volume":"43","author":"Chahal","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib130","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0022-5347(01)62379-6","article-title":"A phase I\/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil, and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer","volume":"160","author":"Zietman","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.soc.2004.11.001_bib131","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0094-0143(03)00061-2","article-title":"Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer","volume":"30","author":"Bochner","year":"2003","journal-title":"Urol Clin North Am"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320704001152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320704001152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:52:37Z","timestamp":1760961157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320704001152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S1055320704001152"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2004.11.001","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder Cancer\u2014Resection\/Ablation","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2004.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}